CClinicalTrials.gg
CompletedNCT07243912Updated Nov 24, 2025

Balance Evaluation in Adult Hemophilia

An observational study in Postural Balance, sponsored by Ayse Merve TAT. Completed at 1 site in Turkey (Türkiye). Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Ayse Merve TAT · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
81
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

Introduction: Recurrent hemarthrosis in hemophilia can cause deterioration of static and dynamic balance in hemophilia. Studies in AwH report decreased dynamic balance, but consistent results regarding static balance are lacking. The causes of the decrease in dynamic balance and its associated parameters have been under explored.

Aim: To investigate static and dynamic balance in AwH compared to healthy controls and factors such as joint health, physical activity and kinesiophobia that may affect dynamic balance.

Methods: This cross-sectional controlled study included 41 AwH and 40 healthy controlled, totally 81 man and study groups determined as Hemophilia Group (HG) and Control Group (CG). Static (Static Stability Test) and dynamic balance (Limits of Stability Test (LoS) Test) were assessed Pro-kin Technobody Posturographic Platform; physical activity level with International Physical Activity Questionnaire (IPAQ) for all groups. Joint health and kinesiophobia were assessed with Hemophilia Joint Health Score and Tampa Scale for Kinesiophobia (TSK) for HG, respectively. Participants' age, height and weight were questioned in both groups, as well as type and severity of hemophilia, type of treatment, and work/job status in HG.

02

Conditions studied

  • Postural Balance

Keywords

  • hemophilia
  • postural balance
  • musculoskeletal disease
  • physical activity
  • kinesiophobia
03

In context

Hemophilia A

866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

This study's enrollment of 81 is close to the median of 80 across 314 observational studies indexed under Hemophilia A.

Browse Hemophilia A studies →

Lead sponsor

This is the only study on the registry with Ayse Merve TAT as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Hemophilia patients and healthy volunteers

Inclusion criteria

Severe or moderate hemophilia A or B

Exclusion criteria

Exclusion Criteria:

Diabetus mellitus, hemiplegia, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, all vestibular system pathologies, lower extremity surgery within the last 6 months, using a walking aid.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
81 participants (actual)
Target follow-up
7 Days
Patient registry
Yes

Groups and cohorts

  • Control Group

    Healthy individual

    Diagnostic Test: Postural balance assessment

  • Hemophilia Group

    Adults with Hemophilia

    Diagnostic Test: Postural balance assessment

Interventions

  • Diagnostic testPostural balance assessment

    Static and dynamic balance was analyzed with the posturographic platform.

06

What researchers measure

Primary outcomes

  1. Static and Dynamic Balance Assessment

    Static and dynamic balance assessments were performed using the Pro-kin Technobody Posturographic Platform (Pro-kin 212, Technobody s.r.l., Dalmine, 21044 Bergamo, Italy). Static balance was assessed using the "Static Stability Test." This test is based on the subject's oscillations on the force platform, assessing the movement of the center of pressure, and the trunk sensor measuring trunk oscillation. Dynamic balance will be assessed using the Limits of Stability test. For the LoS test, a medium difficulty level (20 levels) will be selected from the 5-10-20-30-40 difficulty levels. Participants will be asked to orient their center of gravity toward eight directional targets for a limited time.

    Time frame: From enrollment to at 4 weeks

Secondary outcomes

  1. Joint Health

    This was assessed with Hemophilia Joint Health Score (HJHS). The HJHS evaluates the knee, elbow, and ankle index joints bilaterally and includes a walking score. Each joint can receive a maximum of 20 points, with a maximum walking score of 4 points (total score = 124). A higher score indicates poor joint health. Since the elbow joint score will not be used in this study, the maximum score was determined as 84.

    Time frame: From enrollment to 4 weeks

  2. Physical Activity Level

    Physical activity was evaluated with the International Physical Activity Questionnaire (IPAQ) Short Form. The IPAQ short form consists of seven questions to be answered by the patient and asks about the duration and frequency of each activity performed during the past week. The total score is calculated in MET-min/week by multiplying the MET values defined for walking (3.3 METs), moderate-intensity physical activity (4.0 METs), and vigorous-intensity physical activity (8.0 METs) by the duration (minutes) and frequency (days). Sitting is not included in the score. High scores indicate high physical activity.

    Time frame: From enrollment to 4 weeks

  3. Kinesiophobia

    Kinesiophobia will be assessed with the Tampa Scale for Kinesiophobia. Kinesiophobia is defined as the fear of reinjury and movement due to chronic pain. It consists of 17 questions, with total scores ranging 17-68. The higher the score is the gretaer the level of kinesiophobia, and scores above 37 are considered high kinesiophobia

    Time frame: From enrollment to 4 weeks

07

Study locations

1 site
  • Van Yüzüncü Yıl University
    Van, Tuşba 65080, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07243912
Lead sponsor
Ayse Merve TAT
Responsible party
Ayse Merve TAT (Assistant Professor, Yuzuncu Yil University) — Sponsor-investigator
First posted
Nov 24, 2025
Start date
Sep 10, 2025
Primary completion
Oct 10, 2025
Completion
Oct 20, 2025
Last update
Nov 24, 2025

Study contacts

Ayşe M Tat, Asst Prof
principal investigator · Yuzuncu Yil University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion